BioAgilytix Bioanalytical Lab Welcomes the Phadia 200 to Its Hamburg Laboratory

The Latest News from BioAgilytix

The Great Seal of the State of North Carolina
October 29, 2020

Governor Cooper Announces 878 New Jobs as BioAgilytix Chooses Durham for Major Expansion

Bioanalytical life science company to invest $61.5 million RALEIGH: BioAgilytix Labs, LLC, a leading life science testing company, will create 878 jobs and invest $61.5 million in Durham, Governor Roy…

Read More

Kennon Broadhurst
September 22, 2020

BioAgilytix Welcomes Kennon Broadhurst as Vice President of Global Marketing to Its Commercial Leadership Team

September 22, 2020-Durham, NC-BioAgilytix Labs is pleased to announce the appointment of Kennon Broadhurst to its Commercial Leadership team as Vice President of Global Marketing. Kennon joins BioAgilytix after having…

Read More

August 24, 2020

BioAgilytix’s Durham, North Carolina Laboratory Receives Certificate of Accreditation from COLA

BioAgilytix has received its Certificate of Accreditation for high complexity testing in the diagnostic immunology specialty from the Commission on Office Laboratory Accreditation (COLA) for its U.S. facility in Durham, North Carolina.

Read More

August 19, 2020

BioAgilytix Welcomes Marianne Scheel Fjording, Ph.D. to Team as Scientific Officer

Dr. Fjording will be based at BioAgilytix’s European laboratory in Hamburg, Germany and will provide scientific and regulatory oversight to BioAgilytix’s team in the development and implementation of strategies for bioanalytical assay development and regulated assay validation.

Read More

August 17, 2020

BioAgilytix Labs Launches COVIDence™ Program for COVID-19 Workforce Testing with Support from BRIO Systems

The end-to-end service handles all aspects of sample collection logistics, testing, and results reporting for employers, providing an easy-to-implement solution to effectively mitigate COVID-19 exposure within their workforces.

Read More

BioAgilytix Diagnostics Logo against a black background
August 3, 2020

BioAgilytix Rebrands Its Cambridge Biomedical Diagnostic Testing Division to BioAgilytix Diagnostics

The new name is reflective of BioAgilytix’s plan, which was set forth following its acquisition of Boston-based Cambridge Biomedical in late 2019, to fully integrate Cambridge Biomedical’s clinical and diagnostic testing capabilities into BioAgilytix’s global service offerings.

Read More

BioAgilytix leadership - Dr. Chad Briscoe
June 30, 2020

Chad Briscoe, Ph.D. Joins BioAgilytix Leadership Team as Chief Scientific Officer

In this role, Dr. Briscoe will provide scientific and regulatory oversight to BioAgilytix’s global teams with strategic guidance in line with emerging scientific developments.

Read More

Mike Nicholson, Ph.D. Vice President, Operations
June 25, 2020

BioAgilytix Welcomes Mike Nicholson, Ph.D. to Leadership Team as Vice President, Operations

In this role, Dr. Nicholson will oversee bioanalytical operations and scientific team development across BioAgilytix’s laboratories in both the USA and Europe, with particular focus leading the organization’s Gene and Cell Therapy bioanalytical services.

Read More

COVID-19 testing packages
June 9, 2020

BioAgilytix Launches Customizable Testing Packages Supporting Solutions to Treat and Prevent Spread of COVID-19

BioAgilytix is now offering customizable COVID-19 testing packages with services to address a breadth of sponsor and employer needs stemming from the coronavirus pandemic.

Read More

Frank Horling, Ph.D. Joins BioAgilytix
May 6, 2020

Frank Horling, Ph.D. Joins BioAgilytix Leadership Team as General Manager, Europe

In this role, Dr. Horling will lead Operations, Finance, HR, and Facilities for BioAgilytix’s European business and its laboratory located in Hamburg, Germany.

Read More

BioAgilytix Expert: Jim McNally, Ph.D
April 29, 2020

BioAgilytix Welcomes Jim McNally, Ph.D. to Leadership Team as Chief Scientific Officer

Dr. McNally brings with him an extensive background in bioanalytical assay development and program leadership working for almost 20 years in the pharmaceutical and biotechnology industry.

Read More